Taiko Pharmaceutical Co (TSE:4574) Change In Working Capital : 円0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Taiko Pharmaceutical Co Change In Working Capital?

Taiko Pharmaceutical Co's change in working capital for the quarter that ended in Mar. 2024 was 円0 Mil.

Taiko Pharmaceutical Co's change in working capital for the fiscal year that ended in Dec. 2022 was 円2,201 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Taiko Pharmaceutical Co Change In Working Capital Historical Data

The historical data trend for Taiko Pharmaceutical Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiko Pharmaceutical Co Change In Working Capital Chart

Taiko Pharmaceutical Co Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

-1,515.88

51.01

57.59

4,500.00

2,201.00

Taiko Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Taiko Pharmaceutical Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Taiko Pharmaceutical Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Taiko Pharmaceutical Co (TSE:4574) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taiko Pharmaceutical Co Ltd (TSE:4574) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 34 Third Street, No. 14, Uchihon Suita, Osaka, JPN, 564-0032

Website

http://www.seirogan.co.jp

Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.

Taiko Pharmaceutical Co (TSE:4574) Headlines

No Headlines